Latest Biologic Stories
DUBLIN, June 18, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/4bc2fv/rheumatology) has announced the addition of the "Rheumatology Therapeutics Market to 2018 - Increasing Uptake of Benlysta, Uloric, Krystexxa, and the Launch of Oral Tofacitinib to Spur Growth" [http://www.researchandmarkets.com/research/4bc2fv/rheumatology ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...
SOUTH SAN FRANCISCO, Calif., June 17, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell (EEC) program for the treatment of type 2 diabetes and obesity. EECs represent less than 1% of all gastrointestinal (GI) cells, but produce virtually all of the...
ANNAPOLIS, Md., June 14, 2013 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies. Representative Jim Gerlach (R-PA), introduced H.R. 2315 with lead cosponsor Rep. Richard Neal (D-MA), and Senator Patrick Toomey (R-PA), introduced an identical bill, S. 1128, with lead...
PRINCETON, N.J. and NANJING, China, June 14, 2013 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced that the companies have expanded their strategic relationship formed in 2010. The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia® (abatacept), for...
Featuring the complete collection of podcasts as recorded in the BPI Theater during the 2013 BIO International Convention. Categories include Biosimilars, Single-Use Processing, Cell Therapy, Antibody/Nonantibody Manufacturing, and Vaccine Manufacturing. New York, NY (PRWEB) June 13, 2013 BioProcess International (BPI) announces the online publication of the complete set of BPI Theater podcasts presented during the 2013 BIO International Convention, 22–25 April in Chicago, IL. Now in...
-- Keynote Speaker, Rhonda R. Voskuhl, M.D., Director of the Multiple Sclerosis Program at UCLA, to Address the Role of Estriol in the Treatment of Multiple Sclerosis -- ROCKVILLE, Md., June 13, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it will host a Multiple Sclerosis-Estriol Investor Day on Tuesday, June 25, 2013 from 9:00 a.m. to 11:00 a.m....
THOUSAND OAKS, Calif. and GAITHERSBURG, Md., June 12, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca (AZN), with its biologics research and development arm MedImmune, today announced that they will present data from a Phase 2 study evaluating brodalumab, a human monoclonal antibody targeting the IL-17 receptor, being investigated for the treatment of psoriatic arthritis at the 2013 European League Against Rheumatism (EULAR) Annual Meeting in Madrid, June 12-15, 2013. "The...
PARIS, June 11, 2013 /PRNewswire/ -- AMPLE Study results highlighted during a press conference at the European League Against Rheumatism (EULAR) Annual congress - Year 2 data shows similar efficacy between ORENCIA plus methotrexate (MTX) and Humira plus MTX, consistent with the year 1 result which demonstrated comparable efficacy based on a non-inferiority endpoint for ACR 20 response - Radiographic...
MENLO PARK, Calif., June 4, 2013 /PRNewswire/ -- Protagonist Therapeutics, Inc. today announced the completion of a $14 million Series B venture financing. The financing, led by new investor Johnson & Johnson Development Corporation (JJDC), also included the participation of Series A investors Lilly Ventures and Starfish Ventures (Melbourne, Australia). The new funding will support the discovery and development of Protagonist's pipeline of oral di-sulfide rich peptide (DRP)...
ST LOUIS, June 4, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that SAFC(®) Commercial (www.safcglobal.com), its custom manufacturing services business unit, has won commercial sales and licensing contracts with two leading Asian biopharmaceutical companies for the purchase of CHOZN(®), their off-the-shelf cell line production platform. The contracts feature the CHOZN(®) Platform system as a key component of each customer's global biotherapeutic...
